Renascience

Renascience Pre-Tax Margin

The Pre-Tax Profit Margin of Renascience (4889.T) as of Nov 19, 2026 is -438.01 %. In the previous year, Pre-Tax Profit Margin was 108.34 % — a change of -504.28% (lower).

Pre-Tax Margin

-438.01 %

YoY

-504.28%

Last updated:

Pre-Tax Profit Margin of Renascience is 2026 -438.01 % . Pre-Tax Profit Margin of Renascience was 2025 108.34 % . It decreases by -504.28% lower compared to the previous year.

The Renascience Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2020
-255.56 JPY
Jan 1, 2021
-47.55 JPY
Jan 1, 2022
-181.64 JPY
Jan 1, 2023
-332.03 JPY
Jan 1, 2024
-132.04 JPY
Jan 1, 2025
108.34 JPY
Jan 1, 2026
-438.01 JPY
The Renascience Pre-Tax Margin history
YEARPre-Tax MarginYoY
-438.01 %-504.28%
108.34 %-182.05%
-132.04 %-60.23%
-332.03 %+82.79%
-181.64 %+282.02%
-47.55 %-81.39%
-255.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Pre-Tax Profit Margin of Renascience is -438.01 % in 2026.

Pre-Tax Profit Margin of Renascience changed from 108.34 % to -438.01 %, representing a -504.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Renascience since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Renascience

All Key Metrics — Renascience